SCHEMBL531156

SCHEMBL531156

OCCCCCCCCC=CCCCCCCCCO

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.42
HSD17B10 Q99714 2/20 0.42
ALDH1A1 P00352 1/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
TSHR P16473 1/20 0.42
FAAH O00519 2/20 0.38
TRPV1 Q8NER1 1/20 0.38
CNR1 P21554 1/20 0.37
GMNN O75496 1/20 0.37
USP2 O75604 1/20 0.37
CYP1A2 P05177 1/20 0.37
POLB P06746 1/20 0.37
MAPT P10636 1/20 0.37
CYP2C9 P11712 1/20 0.37
ALOX15 P16050 1/20 0.37
APEX1 P27695 1/20 0.37
CYP2C19 P33261 1/20 0.37
RECQL P46063 1/20 0.37
BLM P54132 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11288862 1.00 LMNA (0.42) LMNAHSD17B10ALDH1A1MEN1KMT2A
SCHEMBL5251136 1.00 LMNA (0.42) LMNAHSD17B10ALDH1A1MEN1KMT2A
SCHEMBL5251134 1.00 LMNA (0.42) LMNAHSD17B10ALDH1A1MEN1KMT2A
SCHEMBL11672499 1.00 LMNA (0.42) LMNAHSD17B10ALDH1A1MEN1KMT2A
SCHEMBL9816485 1.00 LMNA (0.42) LMNAHSD17B10ALDH1A1MEN1KMT2A
SCHEMBL11672493 1.00 LMNA (0.42) LMNAHSD17B10ALDH1A1MEN1KMT2A
SCHEMBL1207736 1.00 LMNA (0.42) LMNAHSD17B10ALDH1A1MEN1KMT2A
SCHEMBL6448104 1.00 LMNA (0.42) LMNAHSD17B10ALDH1A1MEN1KMT2A
SCHEMBL2956122 1.00 LMNA (0.42) LMNAHSD17B10ALDH1A1MEN1KMT2A
SCHEMBL4325633 1.00 LMNA (0.42) LMNAHSD17B10ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2970352-B1 PREPARATION OF ALKENYL GLYCOSIDES WILMAR TRADING PTE LTD (SG) 2020-12-23 EP claimed
US-9266918-B2 Alkenyl glycosides and their preparation ELEVANCE RENEWABLE SCIENCES, INC. (US) 2016-02-23 US claimed
EP-2970352-A1 ALKENYL GLYCOSIDES AND THEIR PREPARATION Elevance Renewable Sciences, Inc. (US) 2016-01-20 EP claimed
WO-2014159211-A1 ALKENYL GLYCOSIDES AND THEIR PREPARATION ELEVANCE RENEWABLE SCIENCES, INC. (US) 2014-10-02 WO claimed
US-20140275506-A1 ALKENYL GLYCOSIDES AND THEIR PREPARATION ELEVANCE RENEWABLE SCIENCES, INC. (US) 2014-09-18 US claimed
EP-1896385-B1 METATHESIS PROCESS FOR PREPARING AN ALPHA, OMEGA -FUNCTIONALIZED OLEFIN DOW GLOBAL TECHNOLOGIES LLC (US) 2013-08-28 EP claimed
US-20130172493-A1 PROCESS FOR MAKING DENDRITIC POLYOLEFINS FROM TELECHELIC POLYCYCLIC OLEFINS EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) 2013-07-04 US claimed
EP-2970522-B1 IN-MOLD COATING OF ROMP POLYMERS MATERIA INC (US) 2025-05-21 EP disclosed
EP-2970352-B1 PREPARATION OF ALKENYL GLYCOSIDES WILMAR TRADING PTE LTD (SG) 2020-12-23 EP disclosed
EP-2321363-B1 TELECHELIC OLEFIN METATHESIS POLYMERS FROM RENEWABLE FEEDSTOCKS MATERIA INC (US) 2020-04-22 EP disclosed
US-9963553-B2 Alternating crystalline-amorphous multiblock copolymer compositions and methods of production thereof EXXONMOBIL CHEMICAL PATENTS INC. (US) 2018-05-08 US disclosed
US-9803046-B2 In-mold coating of ROMP polymers MATERIA, INC. (US) 2017-10-31 US disclosed
US-9758543-B2 Alkenyl glycosides and their preparation ELEVANCE RENEWABLE SCIENCES, INC. (US) 2017-09-12 US disclosed
US-20060177416-A1 Polymer particle delivery compositions and methods of use MEDIVAS, LLC (US) 2006-08-10 US disclosed
WO-2006083874-A2 VACCINE DELIVERY COMPOSITIONS AND METHODS OF USE MEDIVAS, LLC. (US) 2006-08-10 WO disclosed
US-20060024357-A1 Wound healing polymer compositions and methods for use thereof MEDIVAS, LLC (US) 2006-02-02 US disclosed
WO-2005121250-A2 UNSATURATED POLY(ESTER-AMIDE) BIOMATERIALS CORNELL RESEARCH FOUNDATION, INC. (US) 2005-12-22 WO disclosed
US-20050238689-A1 Bioactive stents for type II diabetics and methods for use thereof MEDIVAS, LLC (US) 2005-10-27 US disclosed
WO-2005097186-A2 BIOACTIVE STENTS FOR TYPE II DIABETICS AND METHODS FOR USE THEREOF MEDIVAS, LLC (US) 2005-10-20 WO disclosed
EP-0559072-A2 Moulding compounds and films obtained from polyester moulding composition BASF Aktiengesellschaft (DE) 1993-09-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050238689-A1 Bioactive stents for type II diabetics and methods for use thereof CD47, ITGB2, ITGA2 LMNA 2239/4885HSD17B10 4268/4885ALDH1A1 3282/4885
US-20140275506-A1 ALKENYL GLYCOSIDES AND THEIR PREPARATION FASN, UGCG, ST6GAL1 LMNA 954/4885HSD17B10 96/4885ALDH1A1 99/4885
US-20060024357-A1 Wound healing polymer compositions and methods for use thereof BMP2, GLO1, LANCL2 LMNA 1965/4885HSD17B10 198/4885ALDH1A1 1022/4885
US-20060177416-A1 Polymer particle delivery compositions and methods of use GRPR, PLAUR, PCNP LMNA 295/4885HSD17B10 2600/4885ALDH1A1 3154/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.